NUCLIDIUM AG
PrivateLast Round
Series B
Extension
May 27, 2026
Total Funding Raised
$139.63M
Momentum Score
25 /100
Company Overview
NUCLIDIUM AG is a biotechnology company developing next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials, Medical Imaging
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NUCLIDIUM AG Comps
Public and private peers based on sector, stage, and business model.
NUCLIDIUM AG Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | May 27, 2026 | ||||
| Series B | Jul 10, 2025 | ||||
| Grant | Jun 27, 2022 | ||||
| Grant | Jan 27, 2022 | ||||
| Series A | Jun 23, 2021 | ||||
Grant | Sep 21, 2020 |
Key People
Founding team and executive leadership
NUCLIDIUM AG Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HighLight Capital | Series B |
| European Innovation Council | Grant |
| Highlight Capital | Series B |
| Neva SGR | Series B, Series B Extension |
| DeepTech & Climate Fonds | Series B, Series B Extension |
| VIVES Partners | Series B, Series B Extension |
| Kurma Growth Opportunities Fund | Series B, Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 27, 2026
$33M round led by Angelini Ventures and Kurma Growth Opportunities Fund.
- Sep 16, 2025
Presenting Phase I/II data for neuroendocrine tumor PET-diagnostic at EANM 2025.
NUCLIDIUM AG Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about NUCLIDIUM AG's valuation, stock price, and market status.
